Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intralesional RP2 as Immunoprevention for High-Risk Oral Precancerous Disease (INTERCEPT)

NCT06623110 is registered in ClinicalTrials.gov with Glenn J. Hanna as lead sponsor.

NCT NCT06623110
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06623110 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intralesional RP2 as Immunoprevention for High-Risk Oral Precancerous Disease (INTERCEPT)
Lead sponsor
Glenn J. Hanna
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2025
Completion date
January 1, 2029
Enrollment
25 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk oral precancerous disease